Skip to contentP
Perspective Therapeutics, Inc.
P
CATXPerspective Therapeutics, Inc. Q1 2015 · 10-Q
Revenue$1.04M$1.04M−0.7% vs Q1 2014 Net Income-$785.86K-$785.86KN/M vs Q1 2014 EPS Diluted-$0.01-$0.01N/M vs Q1 2014 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Perspective Therapeutics, Inc. · CIK 728387 · Engraved from SEC EDGAR
Operating Cash Flow-$1,143,186N/M Free Cash Flowderived-$1,150,639N/M Margins · derivedGross margin-5.3%+2.1 pt vs Q1 2014
Operating margin-111.4%+6.2 pt vs Q1 2014
Net margin-75.4%+45.6 pt vs Q1 2014
ended Sep 30, 2014 · filed Nov 14, 2014 · 45 d after period end